Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction

Detalhes bibliográficos
Autor(a) principal: Savas, Murat
Data de Publicação: 2010
Outros Autores: Yeni, Ercan, Verit, Ayhan, Gulum, Mehmet, Aksoy, Nurten, Ciftci, Halil, Celik, Hakim, Altunkol, Adem, Oncel, Halil
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/18464
Resumo: OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p
id USP-19_d4b8351c33e074c353dde0516362bc11
oai_identifier_str oai:revistas.usp.br:article/18464
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction Phosphodiesterase type 5 inhibitorsTadalafil citrateTotal antioxidant statusTotal oxidant statusProlidase OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (pHospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2010-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1846410.1590/S1807-59322010001200014Clinics; Vol. 65 No. 12 (2010); 1311-1314 Clinics; v. 65 n. 12 (2010); 1311-1314 Clinics; Vol. 65 Núm. 12 (2010); 1311-1314 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/18464/20527Savas, MuratYeni, ErcanVerit, AyhanGulum, MehmetAksoy, NurtenCiftci, HalilCelik, HakimAltunkol, AdemOncel, Halilinfo:eu-repo/semantics/openAccess2012-05-23T11:25:42Zoai:revistas.usp.br:article/18464Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-23T11:25:42Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
spellingShingle Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
Savas, Murat
Phosphodiesterase type 5 inhibitors
Tadalafil citrate
Total antioxidant status
Total oxidant status
Prolidase
title_short Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_full Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_fullStr Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_full_unstemmed Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
title_sort Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
author Savas, Murat
author_facet Savas, Murat
Yeni, Ercan
Verit, Ayhan
Gulum, Mehmet
Aksoy, Nurten
Ciftci, Halil
Celik, Hakim
Altunkol, Adem
Oncel, Halil
author_role author
author2 Yeni, Ercan
Verit, Ayhan
Gulum, Mehmet
Aksoy, Nurten
Ciftci, Halil
Celik, Hakim
Altunkol, Adem
Oncel, Halil
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Savas, Murat
Yeni, Ercan
Verit, Ayhan
Gulum, Mehmet
Aksoy, Nurten
Ciftci, Halil
Celik, Hakim
Altunkol, Adem
Oncel, Halil
dc.subject.por.fl_str_mv Phosphodiesterase type 5 inhibitors
Tadalafil citrate
Total antioxidant status
Total oxidant status
Prolidase
topic Phosphodiesterase type 5 inhibitors
Tadalafil citrate
Total antioxidant status
Total oxidant status
Prolidase
description OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p
publishDate 2010
dc.date.none.fl_str_mv 2010-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/18464
10.1590/S1807-59322010001200014
url https://www.revistas.usp.br/clinics/article/view/18464
identifier_str_mv 10.1590/S1807-59322010001200014
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/18464/20527
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 65 No. 12 (2010); 1311-1314
Clinics; v. 65 n. 12 (2010); 1311-1314
Clinics; Vol. 65 Núm. 12 (2010); 1311-1314
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222755626418176

Registros relacionados